Jeffrey S Wefel

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

Walter J Curran, Deborah T Blumenthal, Mark R Gilbert, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer‐related cognitive impairment in adults

Kyle R. Noll, Shelli R Kesler, S. Kesler, 2015, CA: a cancer journal for clinicians.

Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.

Eudocia Q Lee, Martin Bendszus, Gordon J Harris, 2018, The Lancet. Oncology.

OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA , 110 ( 28 ) ISSN 0027-8424

Fumiko Hoeft, S M Hadi Hosseini, Shelli R Kesler, 2013 .

Clinical trial end points for high-grade glioma: the evolving landscape.

Timothy F Cloughesy, Mark R Gilbert, Wolfgang Wick, 2011, Neuro-oncology.

Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.

Maria Werner-Wasik, Tito R Mendoza, Corneel Coens, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

‘Chemobrain’ in breast carcinoma?

R. Theriault, A. Buzdar, R. Lenzi, 2004, Cancer.